The Claim
The Lumipulse G pTau217/β-Amyloid 1-42 plasma ratio, measured in adults aged 50 and older with cognitive complaints, identifies amyloid pathology with 97.6% sensitivity and 90.8% specificity when validated against cerebrospinal fluid biomarkers or amyloid PET imaging.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
A blood test called Lumipulse G pTau217/β-Amyloid 1-42 ratio detects amyloid pathology in adults aged 50 and older with cognitive complaints with 97.6% accuracy for identifying true cases and 90.8% accuracy for ruling out false cases, compared to cerebrospinal fluid tests or amyloid PET scans.
See the scientific wording
The Lumipulse G pTau217/β-Amyloid 1-42 plasma ratio, measured in adults aged 50 and older with cognitive complaints, accurately identifies amyloid pathology with 97.6% sensitivity and 90.8% specificity when validated against cerebrospinal fluid biomarkers or amyloid PET imaging, enabling a non-invasive alternative to invasive or expensive diagnostic procedures in specialized memory clinics.
When amyloid plaques build up in the brain, they cause tau proteins to change shape and spread, and both of these proteins leak into the blood in predictable amounts. The ratio of these two proteins in the blood matches what is happening in the brain, so a high ratio means amyloid plaques are present.
What the research says
1 studyThis blood test checks two proteins in the blood and can tell with very high accuracy whether an older adult with memory problems has amyloid plaques in their brain — just as well as more invasive spinal taps or brain scans.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.